Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Enfortumab Vedotin in Pancreatic Adenocarcinoma
NCT05915351Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in pancreatic adenocarcinoma (PDAC), sponsored by University of Kansas Medical Center. Primary endpoint: Overall Response Rate. Started Jun 2023; status: active, not recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05915351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915351.